Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSTL NASDAQ:PGNY NASDAQ:SGRY NASDAQ:VRDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$22.91+3.6%$21.61$14.59▼$44.28$670.90M1.04328,500 shs305,330 shsPGNYProgyny$27.38+1.8%$23.22$16.10▼$28.75$2.11B1.031.42 million shs795,235 shsSGRYSurgery Partners$15.46+1.6%$14.13$11.41▼$24.10$1.99B1.961.24 million shs1.15 million shsVRDNViridian Therapeutics$17.39+0.4%$16.19$13.18▼$34.29$1.79B0.91.59 million shs1.88 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences+2.50%+9.23%+9.78%-10.45%+15.45%PGNYProgyny+0.98%+2.20%+8.08%+51.15%+26.48%SGRYSurgery Partners+4.75%+6.96%+13.58%+28.44%-27.90%VRDNViridian Therapeutics+0.23%+3.65%+0.46%-38.58%+18.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$22.91+3.6%$21.61$14.59▼$44.28$670.90M1.04328,500 shs305,330 shsPGNYProgyny$27.38+1.8%$23.22$16.10▼$28.75$2.11B1.031.42 million shs795,235 shsSGRYSurgery Partners$15.46+1.6%$14.13$11.41▼$24.10$1.99B1.961.24 million shs1.15 million shsVRDNViridian Therapeutics$17.39+0.4%$16.19$13.18▼$34.29$1.79B0.91.59 million shs1.88 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences+2.50%+9.23%+9.78%-10.45%+15.45%PGNYProgyny+0.98%+2.20%+8.08%+51.15%+26.48%SGRYSurgery Partners+4.75%+6.96%+13.58%+28.44%-27.90%VRDNViridian Therapeutics+0.23%+3.65%+0.46%-38.58%+18.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSTLCastle Biosciences 2.70Moderate Buy$42.4385.20% UpsidePGNYProgyny 2.79Moderate Buy$29.929.26% UpsideSGRYSurgery Partners 2.75Moderate Buy$22.1843.48% UpsideVRDNViridian Therapeutics 2.79Moderate Buy$36.14107.84% UpsideCurrent Analyst Ratings BreakdownLatest CSTL, PGNY, SGRY, and VRDN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026CSTLCastle Biosciences Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.006/22/2026PGNYProgyny Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $33.006/5/2026PGNYProgyny Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/4/2026SGRYSurgery Partners Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/2/2026PGNYProgyny Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$29.00 ➝ $31.006/1/2026CSTLCastle Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/29/2026CSTLCastle Biosciences KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.005/26/2026SGRYSurgery Partners Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/26/2026CSTLCastle Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/19/2026PGNYProgyny Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$19.00 ➝ $30.005/15/2026PGNYProgyny BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$23.00 ➝ $27.00(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSTLCastle Biosciences$344.23M2.02$1.15 per share19.87$16.13 per share1.42PGNYProgyny$1.29B1.66$0.75 per share36.53$5.99 per share4.57SGRYSurgery Partners$3.31B0.61$1.73 per share8.92$24.21 per share0.64VRDNViridian Therapeutics$70.85M25.30N/AN/A$6.18 per share2.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSTLCastle Biosciences-$24.16M-$0.44N/AN/AN/A-3.78%-2.77%-2.30%8/3/2026 (Estimated)PGNYProgyny$58.52M$0.7735.5623.602.375.23%13.34%9.03%8/6/2026 (Estimated)SGRYSurgery Partners-$77.90M-$0.60N/A44.174.55-2.28%1.04%0.41%8/4/2026 (Estimated)VRDNViridian Therapeutics-$342.60M-$3.32N/AN/AN/A-490.31%-80.19%-48.84%8/5/2026 (Estimated)Latest CSTL, PGNY, SGRY, and VRDN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PGNYProgyny$0.2560$0.50+$0.2440$0.29$326.47 million$328.50 million5/6/2026Q1 2026CSTLCastle Biosciences-$0.49-$0.49N/A-$0.49$79.23 million$84.23 million5/5/2026Q1 2026SGRYSurgery Partners-$0.15-$0.03+$0.12-$0.28$797.69 million$810.90 million5/5/2026Q1 2026VRDNViridian Therapeutics-$1.06-$0.90+$0.16-$0.90$0.04 million$0.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCSTLCastle BiosciencesN/AN/AN/AN/AN/APGNYProgynyN/AN/AN/AN/AN/ASGRYSurgery PartnersN/AN/AN/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSTLCastle Biosciences0.026.756.53PGNYProgynyN/A2.132.13SGRYSurgery Partners1.171.861.69VRDNViridian Therapeutics0.1015.1515.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSTLCastle Biosciences92.60%PGNYProgyny94.93%SGRYSurgery PartnersN/AVRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCSTLCastle Biosciences6.10%PGNYProgyny9.90%SGRYSurgery Partners2.00%VRDNViridian Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSTLCastle Biosciences54030.33 million28.48 millionOptionablePGNYProgyny31078.33 million70.58 millionOptionableSGRYSurgery Partners16,000130.79 million128.17 millionOptionableVRDNViridian Therapeutics50103.07 million100.60 millionOptionableCSTL, PGNY, SGRY, and VRDN HeadlinesRecent News About These CompaniesViridian’s VRDN-003 Thyroid Eye Disease Trial Reaches Completion, Resetting the Risk/Reward for InvestorsJune 25 at 12:31 PM | tipranks.comKopp Family Office LLC Trims Stake in Viridian Therapeutics, Inc. $VRDNJune 25 at 5:51 AM | marketbeat.comViridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market AppreciatesJune 25 at 1:23 AM | seekingalpha.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by AnalystsJune 22 at 4:32 AM | americanbankingnews.comPerceptive Advisors LLC Buys 1,580,303 Shares of Viridian Therapeutics, Inc. $VRDNJune 18, 2026 | marketbeat.comViridian Therapeutics, Inc. $VRDN Shares Sold by Eversept Partners LPJune 18, 2026 | marketbeat.comBaker BROS. Advisors LP Grows Stake in Viridian Therapeutics, Inc. $VRDNJune 18, 2026 | marketbeat.com1,500,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Avoro Capital Advisors LLCJune 17, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM) and Viridian Therapeutics (VRDN)June 12, 2026 | theglobeandmail.comViridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comViridian Metals Commences 2026 Diamond Drill Program at the KrakenJune 9, 2026 | globenewswire.comViridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill ProgramJune 5, 2026 | globenewswire.comViridian Therapeutics Fully Repays Loan, Ends AgreementMay 28, 2026 | tipranks.comViridian Therapeutics secures WuXi deal for veligrotug manufacturingMay 26, 2026 | tipranks.comViridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350MMay 21, 2026 | finance.yahoo.comViridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel ProjectMay 19, 2026 | globenewswire.comViridian Therapeutics Announces Presentations at Multiple Medical Meetings in SeptemberMay 17, 2026 | businesswire.comThis Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 MillionMay 17, 2026 | fool.comViridian Metals Announces Flow-Through Private Placement, Warrant Extension and Date of Annual General and Special MeetingMay 14, 2026 | globenewswire.comInsider Buying: Viridian Therapeutics (NASDAQ:VRDN) Director Acquires 1,176,470 Shares of StockMay 14, 2026 | insidertrades.comViridian Therapeutics Raises $359 Million in OfferingsMay 13, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCSTL, PGNY, SGRY, and VRDN Company DescriptionsCastle Biosciences NASDAQ:CSTL$22.91 +0.79 (+3.57%) Closing price 04:00 PM EasternExtended Trading$22.59 -0.32 (-1.41%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Progyny NASDAQ:PGNY$27.38 +0.49 (+1.82%) Closing price 04:00 PM EasternExtended Trading$26.98 -0.40 (-1.44%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.Surgery Partners NASDAQ:SGRY$15.46 +0.24 (+1.58%) Closing price 04:00 PM EasternExtended Trading$15.46 +0.00 (+0.03%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy, and wound care; and ancillary services, including multi-specialty physician practices, urgent care facilities, and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.Viridian Therapeutics NASDAQ:VRDN$17.39 +0.07 (+0.40%) Closing price 04:00 PM EasternExtended Trading$17.44 +0.05 (+0.32%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal MDA Space Targets US Defense Market With $620M Acquisition Qualcomm’s $4B AI Deal Takes Aim at NVIDIA’s Software Moat Cerebras Systems, Inc: The Next Rags-to-Riches AI Story? Domino's Stock Slides to 52-Week Low as Investors Digest CEO Change Getty Images’ OpenAI Deal Gives the Stock a New AI Licensing Story Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
